Skip to main content

Table 2 Patient characteristics regarding MRI follow-up

From: Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases

Characteristics

MRI FU at 3 months

No MRI FU at 3 months

p-value

≥1 MRI per 180 days

< 1 MRI per 180 days

p-value

Gender

  

0.662

  

0.025

 Male

22 (29)

21 (28)

 

17 (23)

26 (35)

 

 Female

18 (24)

14 (19)

 

21 (28)

11 (15)

 

Age at diagnosis (years)

60.6 (33.3–77.2)

64.4 (42.2–79.2)

0.137

61.1 (33.3–79.2)

62.9 (42.2–76.1)

0.511

Histology

  

0.079

  

0.222

 Lung

25 (33)

12 (16)

 

23 (31)

14 (19)

 

 Breast

2 (3)

4 (5)

 

3 (4)

3 (4)

 

 Melanoma

4 (5)

9 (12)

 

5 (7)

8 (11)

 

 RCC

1 (1)

1 (1)

 

0 (0)

2 (3)

 

 Colorectal

2 (3)

6 (8)

 

2 (3)

6 (8)

 

 Other

6 (8)

3 (4)

 

5 (7)

4 (5)

 

Location of cavity

  

0.473

  

0.953

 Supratentorial

32 (42)

29 (38)

 

31 (40)

30 (39)

 

 Infratentorial

10 (13)

6 (8)

 

8 (10)

8 (10)

 

Number of BM

  

0.463

  

0.333

 1

35 (47)

28 (37)

 

34 (45)

29 (39)

 

 2

5 (7)

6 (8)

 

4 (5)

7 (9)

 

 3

0 (0)

1 (1)

 

0 (0)

1 (1)

 

Fractionation

  

0.688

  

0.83

 SRS

32 (43)

28 (36)

 

30 (39)

30 (39)

 

 HFSRT

10 (13)

7 (9)

 

9 (12)

8 (10)

 

ECOG score

  

0.513

  

0.652

 0

30 (40)

24 (32)

 

26 (35)

28 (37)

 

 1

8 (11)

6 (8)

 

8 (11)

6 (8)

 

 2 or NA

2 (3)

5 (7)

 

4 (5)

3 (4)

 

GPA score

  

0.139

  

0.291

 3.5–4

12 (16)

11 (15)

 

10 (13)

13 (17)

 

 2.5–3

22 (29)

13 (17)

 

21 (28)

14 (19)

 

 0–2

4 (5)

9 (12)

 

5 (7)

8 (11)

 

 NA

2 (3)

2 (3)

 

2 (3)

2 (3)

 

BM symptomatic initially

  

0.387

  

0.331

 No or unknown

3 (4)

2 (3)

 

3 (4)

2 (3)

 

 Yes

40 (53)

30 (40)

 

38 (51)

32 (43)

 

Residual tumor

  

0.071

  

0.376

 No

36 (47)

24 (31)

 

32 (42)

28 (36)

 

 Yes

6 (8)

11 (14)

 

7 (9)

10 (13)

 

Systemic cancer treatment

  

0.573

  

0.978

 No or unknown

21 (28)

16 (21)

 

19 (25)

18 (24)

 

 Yes

19 (25)

19 (25)

 

19 (25)

19 (25)

 

  Cytotoxic

14 (19)

11 (15)

 

12 (16)

13 (17)

 

  Immunotherapy/targeted

3 (4)

3 (4)

 

3 (4)

3 (4)

 

  Combined

2 (3)

5 (7)

 

4 (5)

3 (4)

 

Extracranial tumor status

  

0.743

  

0.119

 Stable

16 (21)

11 (15)

 

17 (23)

10 (13)

 

 Progression

22 (29)

22 (29)

 

18 (24)

26 (35)

 

 Unknown

2 (3)

2 (3)

 

3 (4)

1 (1)

 

Initial BMV

0.72 (0.07–11.4)

0.39 (0.05–4.1)

0.015

0.7 (0.12–10.7)

0.39 (0.05–11.4)

0.015

BMV

0.65 (0–84.4)

0 (0–34.8)

0.139

1.33 (0–84.4)

0 (0–34.8)

0.012

  1. Values represent numbers (percent) or median (range) if not specified otherwise
  2. FU follow-up, BM brain metastasis, RCC renal cell carcinoma, SRS stereotactic radiosurgery, HFSRT hypo-fractionated stereotactic radiotherapy, ECOG Eastern Cooperative Oncology Group, GPA Graded Prognostic Assessment, NA not applicable, BMV brain metastasis velocity
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us